Pathology reporting of pancreatic cancer following neoadjuvant therapy: Challenges and uncertainties

Cancer Treatment Reviews

Volumn 41, Issue 1, 2015, Pages 17-26

  Verbeke, C ^a,b   Lohr M ^a   Severin Karlsson, J ^b   Del Chiaro, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Neoadjuvant treatment; Pancreatic cancer; Pathology; Standardization; Tumour regression

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER SURGERY; HUMAN; LABORATORY DIAGNOSIS; LYMPH NODE METASTASIS; MICROSCOPY; PANCREAS CANCER; PATHOLOGY; REVIEW; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION; CANCER GRADING; CARCINOMA, PANCREATIC DUCTAL; MINIMAL RESIDUAL DISEASE; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

CARCINOMA, PANCREATIC DUCTAL; HUMANS; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM, RESIDUAL; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84918836466     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.11.002     Document Type: Review

References (100)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
3. Alexakis N., Halloran C., Raraty M., Ghaneh P., Sutton R., Neoptolemos J.P. Current standards of surgery for pancreatic cancer. Br J Surg 2004, 91:1410-1427.
4. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
5. Crane C.H., Varadhachary G., Wolff R.A., Pisters P.W., Evans D.B. The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol 2006, 20:365-382.
6. Gillen S., Schuster T., Meyer zum Büschenfelde C., Friess H., Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7:e1000267.
7. Belli C., Cereda S., Anand S., Reni M. Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev 2013, 39:518-524.
8. Morganti A.G., Massaccesi M., La Torre G., Caravatta L., Piscopo A., Tambaro R., et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010, 17:194-205.
9. Katz M.H., Pisters P.W., Lee J.E., Fleming J.B. Borderline resectable pancreatic cancer: what have we learned and where do we go from here?. Ann Surg Oncol 2011, 18:608-610.
10. Bockhorn M., Uzunoglu F.G., Adham M., Imrie C., Milicevic M., Sandberg A.A., et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2014, 155:977-988.
11. Katz M.H., Marsh R., Herman J.M., Shi Q., Collison E., Venook A.P., et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013, 20:2787-2795.
12. Royal College of Pathologists Standards and datasets for reporting cancers. Dataset for colorectal cancer histopathology reports 2014, Royal College of Pathologists, London. 3rd ed.
13. Van de Velde C.J., Boelens P.G., Borras J.M., Coebergh J.W., Cervantes A., Blomqvist L., et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer 2014, 50:1. e1-1.e34.
14. Quirke P., Palmer T., Hutchins G.G.A., West N.P. Histopathological work-up of resection specimens, local excisions and biopsies in colorectal cancer. Dig Dis 2012, 30:2-8.
15. Thies S., Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol 2013, 3:262.
16. Strobel O., Berens V., Hinz U., Hartwig W., Hackert T., Bergmann F., et al. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Surgery 2012, 152:S33-S42.
17. Kang C.M., Chung Y.E., Park J.Y., Sung J.S., Hwang H.K., Choi H.J., et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg 2012, 16:509-517.
18. Denost Q., Laurent C., Adam J.P., Capdepont M., Vendrely V., Collet D., et al. Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head. HPB (Oxford) 2013, 15:716-723.
19. Katz M.H., Fleming J.B., Bhosale P., Varadhachary G., Lee J.E., Wolff R., et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012, 118:5749-5756.
20. Chatterjee D., Katz M.H., Rashid A., Estrella J.S., Wang H., Varadhachary G.R., et al. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology 2013, 63:841-851.
21. Ishikawa O., Ohhigashi H., Teshima T., Chatani M., Inoue T., Tanaka S., et al. Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol 1989, 40:143-151.
22. Chatterjee D., Katz M.H., Rashid A., Varadhachary G.R., Wolff R.A., Wang H., et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer 2012, 118:3182-3190.
23. Le Scodan R., Mornex F., Partensky C., Mercier C., Valette P.J., Ychou M., et al. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial. Am J Clin Oncol 2008, 31:545-552.
24. Chun Y.S., Cooper H.S., Cohen S.J., Konski A., Burtness B., Denlinger C.S., et al. Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol 2011, 18:3601-3607.
25. Heinrich S., Schäfer M., Weber A., Hany T.F., Bhure U., Pestalozzi B.C., et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 2008, 248:1014-1022.
26. Heinrich S., Pestalozzi B.C., Schäfer M., Weber A., Bauerfeind P., Knuth A., et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:2526-2531.
27. Turrini O., Viret F., Moureau-Zabotto L., Guiramand J., Moutardier V., Lelong B., et al. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma. Eur J Surg Oncol 2009, 35:1306-1311.
28. Ishikawa O., Ohhigashi H., Sasaki Y., Imaoka S., Iwanaga T., Teshima T., et al. The histopathological effect of preoperative irradiation in adenocarcinoma of the periampullary region. Nihon Gan Chiryo Gakkai Shi 1988, 23:720-727.
29. Evans D.B., Rich T.A., Byrd D.R., Cleary K.R., Connelly J.H., Levin B., et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992, 127:1335-1339.
30. White R.R., Xie H.B., Gottfried M.R., Czito B.G., Hurwitz H.I., Morse M.A., et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 2005, 12:214-221.
31. Washington K, Berlin J, Branton P, Burgart LJ, Carter DK, Compton CC et al. Protocol for the examination of specimens from patients with carcinoma of the exocrine pancreas. College of American Pathologists (2013 Oct 1). Available from: http://www.cap.org.
32. Verbeke C.S., Knapp J., Gladhaug I.P. Tumour growth is more dispersed in pancreatic head cancers than in rectal cancer: implications for resection margin assessment. Histopathology 2011, 59:1111-1121.
33. Fareed K.R., Ilyas M., Kaye P.V., Soomro I.N., Lobo D.N., Parsons S.L., et al. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy. Histopathology 2009, 55:399-406.
34. Verbeke C., Sheridan M., Scarsbrook A., Albazaz R., Smith A., Menon K., et al. How accurate is size assessment of pancreatic head cancers by radiology and pathology?. Pancreatology 2010, 10:300.
35. Chetty R., Gill P., Govender D., Bateman A., Chang H.J., Driman D., et al. A multi-centre pathologist survey on pathological processing and regression grading of colorectal cancer resection specimens treated by neoadjuvant chemoradiation. Virchows Arch 2012, 460:151-155.
36. Lindebjerg J., Hansborg N., Ploen J., Rafaelsen S., Jorgensen J.C., Jakobsen A. Factors influencing reproducibility of tumour regression grading after high-dose chemoradiation of locally advanced rectal cancer. Histopathology 2011, 59:18-21.
37. Bateman A.C., Jaynes E., Bateman A.R. Rectal cancer staging post neoadjuvant therapy - how should the changes be assessed?. Histopathology 2009, 54:713-721.
38. Verbeke C.S. Resection margins in pancreatic cancer. Surg Clin North Am 2013, 93:647-662.
39. Adam I.J., Mohamdee M.O., Martin I.G., Scott N., Finan P.J., Johnston D., et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994, 344:707-711.
40. Wibe A., Rendedal P.R., Svensson E., Norstein J., Eide T.J., Myrvold H.E., et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002, 89:327-334.
41. Campbell F., Smith R.A., Whelan P., Sutton R., Raraty M., Neoptolemos J.P., et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1mm of a resection margin. Histopathology 2009, 55:277-283.
42. Chang D.K., Johns A.L., Merrett N.D., Gill A.J., Colvin E.K., Scarlett C.J., et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009, 27:2855-2862.
43. Delpero J.R., Bachellier P., Regenet N., Le Treut Y.P., Paye F., Carrere N., et al. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford) 2014, 16:20-33.
44. Katz M.H., Wang H., Balachandran A., Bhosale P., Crane C.H., Wang X., et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 2012, 16:68-78.
45. Evans D.B., Varadhachary G.R., Crane C.H., Sun C.C., Lee J.E., Pisters P.W., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3496-3502.
46. Turrini O., Ychou M., Moureau-Zabotto L., Rouanet P., Giovannini M., Moutardier V., et al. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol 2010, 36:987-992.
47. Wilkowski R., Thoma M., Schauer R., Wagner A., Heinemann V. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2004, 28:1011-1018.
48. Zhao Q., Rashid A., Gong Y., Katz M.H., Lee J.E., Wolf R., et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol 2012, 16:29-37.
49. Calvo F.A., Matute R., García-Sabrido J.L., Gómez-Espí M., Martínez N.E., Lozano M.A., et al. Neoadjuvant chemoradiation with tegafur in cancer of the pancreas: initial analysis of clinical tolerance and outcome. Am J Clin Oncol 2004, 27:343-349.
50. Desai S.P., Ben-Josef E., Normolle D.P., Francis I.R., Greenson J.K., Simeone D.M., et al. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol 2007, 25:4587-4592.
51. Kopelson G. Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1983, 9:911-915.
52. Estrella J.S., Rashid A., Fleming J.B., Katz M.H., Lee J.E., Wolf R.A., et al. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2012, 118:268-277.
53. Chatterjee D., Rashid A., Wang H., Katz M.H., Wolff R.A., Varadhachary G.R., et al. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol 2012, 36:552-559.
54. Varadhachary G.R., Wolff R.A., Crane C.H., Sun C.C., Lee J.E., Pisters P.W., et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3487-3495.
55. Chun Y.S., Milestone B.N., Watson J.C., Cohen S.J., Burtness B., Engstrom P.F., et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010, 17:2832-2838.
56. Katz M.H., Pisters P.W., Evans D.B., Sun C.C., Lee J.E., Fleming J.B., et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008, 206:833-846.
57. Murata Y., Mizuno S., Kishiwada M., Hamada T., Usui M., Sakurai H., et al. Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Pancreas 2012, 41:130-136.
58. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
59. Stokes J.B., Nolan N.J., Stelow E.B., Walters D.M., Weiss G.R., de Lange E.E., et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011, 18:619-627.
60. Dudeja V., Greeno E.W., Walker S.P., Jensen E.H. Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression. HPB (Oxford) 2013, 15:661-667.
61. Arvold N.D., Ryan D.P., Niemierko A., Blaszkowsky L.S., Kwak E.L., Wo J.Y., et al. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer 2012, 118:3026-3035.
62. Duldulao M.P., Lee W., Streja L., Chu P., Li W., Chen Z., et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis Colon Rectum 2013, 56:142-149.
63. Blaauwgeers J.L., Kappers I., Klomp H.M., Belderbos J.S., Dijksman L.M., Smit E.F., et al. Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. Virchows Arch 2013, 462:547-556.
64. Nakamura T., Kuwai T., Kitadai Y., Sasaki T., Fan D., Coombes K.R., et al. Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res 2007, 67:7597-7604.
65. Niedergethmann M., Alves F., Neff J.K., Heidrich B., Aramin N., Li L., et al. Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 2007, 97:1432-1440.
66. Kim H.J., Czischke K., Brennan M.F., Conlon K.C. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?. J Gastrointest Surg 2002, 6:763-769.
67. Verbeke C.S., Gladhaug I.P. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg 2012, 99:1036-1049.
68. Wanebo H.J., Glicksman A.S., Vezeridis M.P., Clark J., Tibbetts L., Koness R.J., et al. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg 2000, 135:81-87.
69. Brunner T.B., Grabenbauer G.G., Kastl S., Herrmann O., Baum U., Fietkau R., et al. Preoperative chemoradiation in locally advanced pancreatic carcinoma: a phase II study. Onkologie 2000, 23:436-442.
70. Snady H., Bruckner H., Cooperman A., Paradiso J., Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000, 89:314-327.
71. Adhoute X., Smith D., Vendrely V., Rault A., Sa Cunha A., Legoux J.L., et al. Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy. Gastroenterol Clin Biol 2006, 30:224-230.
72. Massucco P., Capussotti L., Magnino A., Sperti E., Gatti M., Muratore A., et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006, 13:1201-1208.
73. Pomianowska E., Clausen O.P.F., Gladhaug I.P. Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer. Eur J Surg Oncol 2012, 38:1043-1050.
74. Spitz F.R., Abbruzzese Jl, Lee J.E., Pisters P.W.T., Lowy A.M., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997, 15:928-937.
75. Albores Saavedra J., Simpson K., Dancer Y.J., Hruban R. Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann Diagn Pathol 2007, 11:3-9.
76. Westgaard A., Tafjord S., Farstad I.N., Cvancarova M., Eide T.J., Mathisen O., et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008, 8:170.
77. Westgaard A., Pomianowska E., Clausen O.P., Gladhaug I.P. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?. Ann Surg Oncol 2013, 20:430-439.
78. Bronsert P., Kohler I., Werner M., Makowiec F., Kuesters S., Hoeppner J., et al. Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin. BMC Cancer 2013, 13:428.
79. De Jong M.C., Tsai S., Cameron J.L., Wolfgang C.L., Hirose K., van Vledder M.G., et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol 2010, 102:256-263.
80. Michalski C.W., Erkan M., Hüser N., Müller M.W., Hartel M., Friess H., et al. Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg 2008, 25:473-480.
81. Hruban R.H., Boffetta P., Hiraoka N., Iacobuzio-Donahue C., Kato Y., Kern S.E., et al. Ductal adenocarcinoma of the pancreas. WHO classification of tumors of the digestive system 2010, 280-295. IARC, Lyon. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.).
82. Becker K., Mueller J.D., Schulmacher C., Ott K., Fink U., Busch R., et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003, 98:1521-1530.
83. Aktepe F., Kapucuoglu N., Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology 1996, 29:63-67.
84. Artinyan A., Anaya D.A., McKenzie S., Ellenhorn J.D., Kim J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 2011, 117:2044-2049.
85. Barbier L., Turrini O., Grégoire E., Viret F., Le Treut Y.P., Delpero J.R. Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival. HPB (Oxford) 2011, 13:64-69.
86. Bollschweiler E., Hölscher A.H., Metzger R., Besch S., Mönig S.P., Baldus S.E., et al. Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg 2011, 92:2020-2027.
87. Caricato M., Ausania F., De Dominicis E., Vincenzi B., Rabitti C., Tonini G., et al. Tumor regression in mesorectal lymphnodes after neoadjuvant chemoradiation for rectal cancer. Eur J Surg Oncol 2007, 33:724-728.
88. Newman L.A., Pernick N.L., Adsay V., Carolin K.A., Philip P.A., Sipierski S., et al. Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 2003, 10:734-739.
89. Mirbagheri N., Kumar B., Deb S., Poh B.R., Dark J.G., Leow C.C., et al. Lymph node status as a prognostic indicator after preoperative neoadjuvant chemoradiotherapy of rectal cancer. Colorectal Dis 2014, [Epub ahead of print]. 10.1111/codi.1268.
90. Chatterjee D., Katz M.H., Rashid A., Wang H., Iuga A.C., Varadhachary G.R., et al. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 2012, 36:409-417.
91. Yoshioka T., Hosoda M., Yamamoto M., Taguchi K., Hatanaka K.C., Takakuwa E., et al. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer 2013, [Published Online First]. 10.1007/s12282-013-0474-2.
92. Von Minckwitz G., Schmitt W.D., Loibl S., Müller B.M., Blohmer J.U., Sinn B.V., et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 2013, 19:4521-4531.
93. Crane C.H. Is personalization of care coming to pancreatic oncology?. Ann Surg Oncol 2013, 20:355-356.
94. Wei C.H., Gorgan T.R., Elashoff D.A., Hines O.J., Farrell J.J., Donahue T.R. A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas 2013, 42:1303-1310.
95. Saif M.W., Lee Y., Kim R. Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol 2012, 4:341-346.
96. Bhutani M.S. The year of improved tissue acquisition, randomized trials, and endoscopic ultrasound-guided therapy. Endoscopy 2011, 43:993-999.
97. Standards and datasets for reporting cancer. Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct. 2nd ed. London: The Royal College of Pathologists; 2010.
98. Björnstedt M, Franzén L, Glaumann H, Nordlinder H, Palmqvist R, Rissler P et al. Gastrointestinal pathology - pancreas and peri-ampullary region. Recommendations from the KVAST Study Group of the Swedish Society for Pathology (2012). Available from: [accessed 21.08.14]. http://www.svfp.se/files/docs/kvast/leverpatologi/Pankreas%20dok%202012.doc.
99. Royal College of Pathologists of Australasia Cancer of the exocrine pancreas, ampulla of Vater and distal common bile duct, structured reporting protocol 2014, Springer, NY, Available from: http://www.rcpa.edu.au/Library/Practising-Pathology/Structured-Pathology-Reporting-of-Cancer/Cancer-Protocols (accessed 2014 Aug 21). 1st ed.
100. Campbell F., Verbeke C.S. Pathology of the pancreas - a practical approach 2013, Springer Verlag, London, [p. 27-43, 146-151].